Results 21 to 30 of about 5,159 (158)

Effectiveness, Adherence, and Safety of Evolocumab in a Swiss Multicenter Prospective Observational Study [PDF]

, 2022
The aims of this study were to describe patient characteristics, lipid parameters, lipid-lowering drug use, and safety of patients receiving evolocumab in a real-world clinical setting.; We conducted a 1-year multicenter observational study of adults ...
Mach, François, Rossi, Mariagrazia, Carballo, David Andrés, Mueller, Christian, Carballo, David, Koskinas, Konstantinos C., Rickli, Hans, Crljenica, Carmela, Nanchen, David, Sudano, Isabella, Koskinas, Konstantinos C, Bilz, Stefan, Reichert, Nina   +12 more
core   +2 more sources

Evaluation of evolocumab on saphenous vein graft patency following coronary artery bypass graft surgery in people living with and without diabetes in the NEWTON-CABG CardioLink-5 trial. [PDF]

Diabetes Obes Metab
Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4376-4381, May 2026.
Teoh H, Verma S, Mancini GBJ, Quan A, Szarek M, Elituv R, Verma M, Misner E, Krishnaraj A, Jüni P, Koren MJ, Nicholls SJ, Bhatt DL, Mazer CD, Leiter LA.   +14 more
europepmc   +2 more sources

Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study [PDF]

, 2020
Background: People living with human immunodeficiency virus (PLHIV) are at increased risk of atherosclerotic cardiovascular disease (ASCVD) and are prone to statin-related adverse events from drug-drug interactions with certain antiretroviral regimens ...
Kumar, Princy N, Rosenson, Robert S, Cyrille, Marcoli, Calmy, Alexandra, López, J Antonio G, Caramelli, Bruno, Bray, Sarah, BEIJERINCK Investigators, Boccara, Franck   +8 more
core   +2 more sources

Evolocumab and clinical outcomes in patients with cardiovascular disease [PDF]

, 2017
BACKGROUND Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approxi - mately 60%.
Giugliano, Robert P, Thomas Liu, Keech, AC, Robert P. Giugliano, Narimon Honarpour, Kuder, Julia F., Sabatine, Marc S., Sever, Peter S., Stephen D. Wiviott, Liu, Thomas, Pedersen, Terje Rolf, Wasserman, Scott M, Murphy, Sabina A., Sabatine, Marc S, Keech, Anthony C, Scott M. Wasserman, Pedersen, Terje R., Sabatine, MS, Wang, Huei, Kuder, Julia F, Marc S. Sabatine, Sever, PS, Murphy, Sabina A, Pedersen, Terje R, Peter S. Sever, Terje R. Pedersen, Wiviott, Stephen D., Giugliano, RP, Rietzschel, Ernst, Huei Wang, Liu, T, Murphy, SA, Honarpour, N, Gonnelli, Stefano, Wang, H, FOURIER Steering committee and investigators, for the, Wiviott, SD, Julia F. Kuder, Wasserman, Scott M., Wasserman, SM, Giugliano, Robert P., Sever, Peter S, FOURIER Steering Committee and Investigators, Kuder, JF, Pedersen, TR, Anthony C. Keech, Sabina A. Murphy, Honarpour, Narimon, Keech, Anthony C., Wiviott, Stephen D   +49 more
core   +7 more sources

Effect of evolocumab on cholesterol synthesis and absorption[S]

Journal of Lipid Research, 2016
The effects of cholesterol-lowering drugs, including those that reduce cholesterol synthesis (statins) and those that reduce cholesterol absorption (ezetimibe), on cholesterol absorption and synthesis are well understood. Proprotein convertase subtilisin/
Matthew Peach, Ren Xu, Dan Fitzpatrick, Lisa Hamilton, Ransi Somaratne, Robert Scott, Scott M. Wasserman, C. Stephen Djedjos   +7 more
doaj   +1 more source

Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat

Frontiers in Cardiovascular Medicine, 2022
AimsThe efficacy of anti-proprotein convertase subtilisin/Kexin type 9 (PCSK9) monoclonal antibodies in patients with atherosclerotic cardiovascular disease (ASCVD) remains unclear.
Hong-Fei Wang, Hong-Fei Wang, Yu-Cheng Mao, Yu-Cheng Mao, Xin-Yi Xu, Xin-Yi Xu, Si-Yu Zhao, Si-Yu Zhao, Dan-Dan Han, Dan-Dan Han, Shi-Yao Ge, Shi-Yao Ge, Kai Song, Kai Song, Chang Geng, Chang Geng, Qing-Bao Tian, Qing-Bao Tian   +17 more
doaj   +1 more source

Efficacy of single-dose evolocumab injection in early-phase acute myocardial infarction: a retrospective single-center study [PDF]

The Korean Journal of Internal Medicine
Background/Aims Achieving rapid reduction of low-density lipoprotein cholesterol (LDL-C) levels below 55 mg/dL in patients with acute myocardial infarction (AMI) can be challenging with statins alone.
Yongcheol Kim, Ji Woong Roh, Oh-Hyun Lee, Seok-Jae Heo, Eui Im, Deok-Kyu Cho, Byeong-Keuk Kim   +6 more
doaj   +1 more source

Effect of Early Initiation of Evolocumab on Lipoprotein(a) in Patients with Acute Myocardial Infarction: Sub-Analysis of a Randomized Controlled Trial

Journal of Cardiovascular Development and Disease, 2022
Elevated circulating lipoprotein(a) levels are associated with an increased risk of cardiovascular events. We reported that early initiation of evolocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, in addition to a statin substantially ...
Tomoaki Okada, Toru Miyoshi, Masayuki Doi, Kazumasa Nosaka, Ryu Tsushima, Satoko Ugawa, Wataru Takagi, Masahiro Sogo, Masahiko Takahashi, Hiroshi Ito   +9 more
doaj   +1 more source

Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction

, 2022
OBJECTIVES The purpose of this study was to determine the effect of evolocumab on optical coherence tomography (OCT) measures of plaque composition.
Prati, Francesco, Rishi Puri, Huei Wang, Daniel Aradi, Jones, Stephen, Nissen, Steven E, Thomas Hucko, Hucko, Thomas, Kataoka, Yu, Wang, Bei, Giuseppe Di Giovanni, Puri, Rishi, Stephen Jones, Psaltis, Peter J, Gianluca Pompili, Butters, Julie, Julie Butters, Francesco Prati, Yu Kataoka, Windecker, Stephan, Herrman, Jean-Paul R, Di Giovanni, Giuseppe, Renicus S. Hermanides, Bei Wang, Peter J. Psaltis, Wang, Huei, Hermanides, Renicus S, Aradi, Daniel, Stephen J. Nicholls, Stephan Windecker, Pompili, Gianluca, Jean-Paul R. Herrman, Steven E. Nissen, Nicholls, Stephen J   +33 more
core   +1 more source

Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia [PDF]

, 2020
BACKGROUND Evolocumab, a fully human monoclonal antibody directed against proprotein convertase subtilisin–kexin type 9, is widely used in adult patients to lower low-density lipoprotein (LDL) cholesterol levels.
Hamer, Andrew, Mach, François, Kastelein, John JP, Santra, Saikat, Gaudet, Daniel, Descamps, Olivier S., Santos, Raul D, Bergeron, Jean, Descamps, Olivier S, Wiegman, Albert, Hovingh, G. Kees, HAUSER-RCT Investigators, Kastelein, John J.P., Greber-Platzer, Susanne, Stefanutti, Claudia, Kurtz, Christopher E., Chir, B., Bartuli, Andrea, Santos, Raul D., Sokal, Etienne, Szamosi, Tamás, Luirink, Ilse, Ruzza, Andrea, Bridges, Ian, Kastelein, John J. P., Hovingh, Kees   +25 more
core   +1 more source